Navigation Links
Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
Date:4/22/2008

'United Kingdom Needs to Wake Up to Threat of Bioterrorism,' Says UK Board

Member General Lord Guthrie

BOSTON, April 22 /PRNewswire/ -- BioDefense Corp., the only company in the world to develop and deploy technology that can neutralize and destroy a biohazardous substance while maintaining the integrity of the tainted materials, today announced it has partnered with General Lord Guthrie, former chief of the British Defense Staff, to establish new security markets for the BioDefense MailDefender(R) in the United Kingdom.

The BioDefense MailDefender system was developed to give organizations increased control over a potentially uncontrollable situation -- the risk of bio-contamination through the mail. This first-of-its kind system decontaminates mail at the point of entry, protecting employees from harm and organizations from the threats of an actual attack or a disruptive hoax.

The MailDefender(R) is currently deployed at the United Nations, U.S. Department of Justice, U.S. Department of Defense, Department of Alcohol, Tobacco and Firearms and several embassies worldwide.

The directors of BioDefense Corp. are hosting an event today to celebrate the partnership between the United States and the United Kingdom. General Lord Guthrie, member of the House of Lords and new member of the BioDefense advisory board, will speak at the company's new Boston world headquarters about the challenges of and solutions to biological threats.

Said BioDefense Executive Vice President Jonathan Morrone: "We are a global company helping countries and corporations worldwide keep their people safe from biological threats, whether the threats originate domestically or internationally. We believe our partnership with General Lord Guthrie and our two countries will further our nations' abilities to defend against bioterrorism, as well as the security hoaxes that often cripple productivity in government agencies and corporate enterprises."

General Charles Ronald Llewelyn Guthrie, Baron Guthrie of Craigiebank, GCB, LVO, OBE, DL became Assistant Chief of the General Staff in 1987 and in 1989 General Officer Commanding 1st British Corps. In 1992 he took command of the British Army of the Rhine and in 1997 became Chief of the General Staff.

Said Lord Guthrie: "The United Kingdom needs to wake up to the threat of bioterrorism, which is far more serious than defense experts realize, and a national strategy to counter bioterrorism needs to be developed."

"A biological attack is likely to be far more devastating than the 9/11 attacks and can cause significantly far more deaths than the number of people who were killed in the Twin Towers attack in New York City," said the Lord Guthrie. He went on to say that, "It is sobering to remember that far more people were killed by Spanish Flu immediately after World War I than hostilities during the war."

Lord Guthrie is an independent member of the House of Lords. He was created a life peer as Baron Guthrie of Craigiebank, of Craigiebank in the City of Dundee, after retiring as Chief of the Defense Staff. He is a director on the board of Colt Defense LLC and Peter Hambro Mining. Lord Guthrie is also the president of several charities, including Action Medical Research, Army Benevolent Fund, Federation of London Youth Clubs and the Progressive Supranuclear Palsy Association.

About BioDefense Corporation

BioDefense Corp. is currently the only company in the world to develop and deploy technology that can neutralize and destroy a biohazardous substance, such as anthrax, ricin and influenza, while maintaining the integrity of mail, packages, currency and medical waste. The process takes about 45 minutes and can be completed in the field or in a small office environment. BioDefense is dedicated to developing advanced technologies and products designed to create safer, healthier home and work environments. BioDefense products and systems help protect people from harmful biological agents and health hazards that are found in many everyday situations. These hazards range from contaminated or infected mail, to microbially contaminated food, to bio-hazardous medical waste and other public health and safety concerns. Visit http://www.biod.com for more information.


'/>"/>
SOURCE BioDefense Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
2. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
3. Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference
4. Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board
5. HHS Secretary Leavitt Announces Members of the National Biodefense Science Board
6. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
7. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
8. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
9. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
10. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
11. BioMagnetics Diagnostics Corp. Rated Speculative Buy, Target Price $1.42 by Beacon Equity Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):